Resona Asset Management Co. Ltd. Acquires New Holdings in DaVita Inc. (NYSE:DVA)

Resona Asset Management Co. Ltd. acquired a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 14,302 shares of the company's stock, valued at approximately $2,149,000.

A number of other institutional investors have also made changes to their positions in DVA. MML Investors Services LLC lifted its holdings in DaVita by 1.3% in the 3rd quarter. MML Investors Services LLC now owns 5,300 shares of the company's stock worth $869,000 after buying an additional 68 shares in the last quarter. Exchange Traded Concepts LLC increased its position in shares of DaVita by 8.3% during the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock worth $133,000 after acquiring an additional 68 shares during the last quarter. Impact Partnership Wealth LLC lifted its stake in shares of DaVita by 3.7% in the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company's stock worth $290,000 after acquiring an additional 70 shares in the last quarter. Contravisory Investment Management Inc. boosted its holdings in DaVita by 1.2% in the fourth quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company's stock valued at $910,000 after purchasing an additional 73 shares during the last quarter. Finally, Nilsine Partners LLC grew its stake in DaVita by 0.8% during the 4th quarter. Nilsine Partners LLC now owns 11,160 shares of the company's stock valued at $1,669,000 after purchasing an additional 92 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Cowen reiterated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. StockNews.com upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research note on Thursday, April 10th. Barclays boosted their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $166.33.

DaVita Stock Performance

Shares of NYSE:DVA traded down $3.51 on Tuesday, reaching $147.37. 198,150 shares of the company's stock were exchanged, compared to its average volume of 823,013. DaVita Inc. has a fifty-two week low of $125.64 and a fifty-two week high of $179.60. The business's 50-day moving average is $151.61 and its two-hundred day moving average is $156.51. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The firm has a market capitalization of $11.79 billion, a price-to-earnings ratio of 13.71, a PEG ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, equities research analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.